Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.44 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.44 |
| ▸ | VIPR1 | P32241 | 3/20 | 0.43 |
| ▸ | VIPR2 | P41587 | 4/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.40 |
| ▸ | GLP1R | P43220 | 1/20 | 0.40 |
| ▸ | GCGR | P47871 | 1/20 | 0.40 |
| ▸ | GIPR | P48546 | 1/20 | 0.40 |
| ▸ | NPY2R | P49146 | 6/20 | 0.39 |
| ▸ | NPY4R | P50391 | 6/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.39 |
| ▸ | NPY1R | P25929 | 4/20 | 0.39 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24451291 | 1.00 | SIRT2 (0.44) | SIRT2SIRT5VIPR1VIPR2OPRL1 | |
| SCHEMBL31013467 | 0.98 | SIRT2 (0.43) | SIRT2SIRT5VIPR1VIPR2OPRL1 | |
| SCHEMBL31013475 | 0.98 | SIRT2 (0.43) | SIRT2SIRT5VIPR1VIPR2OPRL1 | |
| SCHEMBL30543724 | 0.91 | SIRT2 (0.44) | SIRT2SIRT5VIPR1VIPR2OPRL1 | |
| SCHEMBL31031511 | 0.90 | SIRT2 (0.43) | SIRT2SIRT5VIPR1OPRL1NPY4R | |
| SCHEMBL29648240 | 0.90 | EPHA2 (0.42) | SIRT2SIRT5VIPR1GLP1RGCGR | |
| SCHEMBL30988493 | 0.88 | NPY4R (0.43) | SIRT2SIRT5VIPR1NPY2RNPY4R | |
| SCHEMBL31031560 | 0.87 | TFPI (0.49) | VIPR1GLP1RGCGRGIPRNPY2R | |
| SCHEMBL29390888 | 0.86 | NPY5R (0.40) | SIRT2SIRT5NPY2RNPY4RNPY5R | |
| SCHEMBL29883866 | 0.86 | SIRT2 (0.44) | SIRT2SIRT5OPRL1NPY2RNPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12599684-B2 | Molecular probes and methods of use | CASE WESTERN RESERVE UNIVERSITY (US) | 2026-04-14 | — | — | US | disclosed |
| US-12576168-B2 | Peptide PET/SPECT probes specific to oncoproteins in tumor extracellular matrix | CASE WESTERN RESERVE UNIVERSITY (US) | 2026-03-17 | — | — | US | disclosed |
| US-20240325574-A1 | EXTRADOMAIN B FIBRONECTIN TARGETING PEPTIDES AND DERIVATIVES FOR CANCER IMAGING AND THERAPY | MOLECULAR THERANOSTICS, LLC | 2024-10-03 | — | — | US | disclosed |
| US-20240156995-A1 | MOLECULAR PROBES AND METHODS OF USE | UNIV CASE WESTERN RESERVE (US) | 2024-05-16 | — | — | US | disclosed |
| US-11738099-B2 | Molecular probes and methods of use | CASE WESTERN RESERVE UNIVERSITY (US) | 2023-08-29 | — | — | US | disclosed |
| US-20220160903-A1 | PEPTIDE PET/SPECT PROBES SPECIFIC TO ONCOPROTEINS IN TUMOR EXTRACELLULAR MATRIX | CASE WESTERN RESERVE UNIVERSITY | 2022-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240156995-A1 | MOLECULAR PROBES AND METHODS OF USE | EDNRB, FGB, FN1 | SIRT2 4463/4885SIRT5 4037/4885VIPR1 798/4885 |
| US-11738099-B2 | Molecular probes and methods of use | DDX21, FUS, DDIT3 | SIRT2 4686/4885SIRT5 4487/4885VIPR1 443/4885 |
| US-20220160903-A1 | PEPTIDE PET/SPECT PROBES SPECIFIC TO ONCOPROTEINS IN TUMOR EXTRACELLULAR MATRIX | FN1, EDNRB, NGLY1 | SIRT2 3136/4885SIRT5 2905/4885VIPR1 647/4885 |
| US-12576168-B2 | Peptide PET/SPECT probes specific to oncoproteins in tumor extracellular matrix | FN1, INHA, EDNRB | SIRT2 4303/4885SIRT5 3528/4885VIPR1 542/4885 |
| US-20240325574-A1 | EXTRADOMAIN B FIBRONECTIN TARGETING PEPTIDES AND DERIVATIVES FOR CANCER IMAGING AND THERAPY | FN1, FGB, QPCTL | SIRT2 1648/4885SIRT5 1746/4885VIPR1 1079/4885 |
| US-12599684-B2 | Molecular probes and methods of use | TFRC, FGB, SSTR3 | SIRT2 3963/4885SIRT5 2890/4885VIPR1 995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.